1. 2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer. (20th October 2022) Authors: Harter, Philipp; Marmé, Frederik; Pietzner, Klaus; Reuss, Alexander; Ray-Coquard, Isabelle; Redondo, Andrés; Oaknin, Ana; Jonuskiene, Goda; Lindemann, Kristina; Kurzeder, Christian; Huober, Jens; van Nieuwenhuysen, Els; Henry, Stephanie; Marth, Christian; Tsibulak, Irina; Cron, Nadin; Pautier, Pa... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗